創薬における人工知能（AI）の世界市場予測（～2024年）...市場調査レポートについてご紹介

1 Introduction (Page No. – 17)
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered for the Study
1.4 Currency
1.5 Limitations
1.6 Stakeholders
2 Research Methodology (Page No. – 21)
2.1 Research Data
2.1.1 Secondary Sources
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Sources
2.1.2.1 Key Data From Primary Sources
2.1.2.2 Key Industry Insights
2.2 Market Size Estimation
2.3 Market Breakdown and Data Triangulation
2.4 Assumptions for the Study
3 Executive Summary (Page No. – 30)
4 Premium Insights (Page No. – 35)
4.1 Market Overview
4.2 Market, By Offering (2019–2024)
4.3 Market for Machine Learning, By Type & Region (2018)
4.4 Market: Geographic Growth Opportunities
5 Market Overview (Page No. – 39)
5.1 Introduction
5.2 Market Dynamics
5.2.1 Market Drivers
5.2.1.1 Growing Number of Cross-Industry Collaborations and Partnerships
5.2.1.2 Need to Control Drug Discovery & Development Costs and Reduce Time
5.2.1.3 Patent Expiry
5.2.2 Market Opportunities
5.2.2.1 Growing Biotechnology Industry
5.2.2.2 Emerging Markets
5.2.3 Market Challenges
5.2.3.1 Limited Availability of Data Sets
6 Market, By Offering (Page No. – 43)
6.1 Introduction
6.2 Software
6.2.1 Benefits Offered By Software in Drug Discovery & Strong Demand Among End Users are Driving Market Growth
6.3 Services
6.3.1 Services Segment to Witness the Highest Growth During the Forecast Period
7 Market, By Technology (Page No. – 48)
7.1 Introduction
7.2 Machine Learning
7.2.1 Increasing Adoption of Ml By Research Centers & Pharmaceutical Companies to Support the Growth of This Segment
7.2.2 Deep Learning
7.2.3 Supervised Learning
7.2.4 Reinforcement Learning
7.2.5 Unsupervised Learning
7.2.6 Other Machine Learning Technologies
7.3 Other Technologies
8 Market, By Application (Page No. – 63)
8.1 Introduction
8.2 Immuno-Oncology
8.2.1 High Prevalence of Cancer and Shortage in the Supply of Cancer Drugs are the Key Factors Driving Market Growth
8.3 Neurodegenerative Diseases
8.3.1 AI is Being Used to Resolve Existing Challenges in Neurological Disease Drug Development
8.4 Cardiovascular Disease
8.4.1 Rising Demand for Cvd Drugs is Driving Market Growth
8.5 Metabolic Diseases
8.5.1 Role of AI in Uncovering Small-Molecule Therapies is Driving Its Adoption in This Segment
8.6 Other Applications
9 Market, By End User (Page No. – 74)
9.1 Introduction
9.2 Pharmaceutical & Biotechnology Companies
9.2.1 Rising Demand for Solutions to Cut Time and Costs of Drug Development have Drawn End-User Attention to AI
9.3 Contract Research Organizations
9.3.1 Growing Trend of Outsourcing Provides Significant Opportunities for Cros
9.4 Research Centers and Academic & Government Institutes
9.4.1 This Segment is Expected to Grow at the Highest CAGR During the Forecast Period
10 Market, By Region (Page No. – 82)
10.1 Introduction
10.2 North America
10.2.1 US
10.2.1.1 Strong Economy and Trend of Early Adoption of Technologies are Driving Market Growth in the US
10.2.2 Canada
10.2.2.1 Growing Research on AI Technologies and Emergence of New Ai-Based Start-UPS Will Support the Market in Canada
10.2.3 Mexico
10.2.3.1 Government Initiatives Will Support Market Growth in Mexico
10.3 Europe
10.3.1 UK
10.3.1.1 The UK Holds the Largest Share of the European Market
10.3.2 Germany
10.3.2.1 Government Support and Favorable Training Programs are Major Market Drivers in Germany
10.3.3 France
10.3.3.1 Strong Government Support and Favorable Strategies & Initiatives Form Key Drivers of the Market in France
10.3.4 Rest of Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.1.1 Japan Dominates the APAC Market for AI in Drug Discovery
10.4.2 China
10.4.2.1 Growing Cmos Market and Cross-Industry Collaborations are Factors Responsible for the Growth of the Market in China
10.4.3 India
10.4.3.1 Steady Adoption of AI Technologies Will Drive Market Growth in India
10.4.4 Rest of Asia Pacific
10.5 Rest of the World
11 Competitive Landscape (Page No. – 114)
11.1 Overview
11.2 Market Share Analysis
11.3 Competitive Leadership Mapping
11.3.1 Visionary Leaders
11.3.2 Dynamic Differentiators
11.3.3 Innovators
11.3.4 Emerging Companies
11.4 Competitive Situation and Trends
11.4.1 Product Launches and Enhancements
11.4.2 Expansions
11.4.3 Acquisitions
11.4.4 Other Strategies
12 Company Profiles (Page No. – 121)
(Business Overview, Products Offered, Recent Developments, MnM View)*
12.1 Microsoft Corporation
12.2 NVIDIA Corporation
12.3 IBM Corporation
12.4 Google (A Subsidiary of Alphabet Inc.)
12.5 Atomwise, Inc.
12.6 Deep Genomics
12.7 Cloud Pharmaceuticals, Inc.
12.8 Insilico Medicine
12.9 Benevolentai
12.10 Exscientia
12.11 Cyclica
12.12 Bioage
12.13 Numerate
12.14 Numedii, Inc.
12.15 Envisagenics
12.16 Twoxar, Incorporated
12.17 Owkin, Inc.
12.18 Xtalpi, Inc.
12.19 Verge Genomics
12.20 Berg LLC
*Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View Might Not Be Captured in Case of Unlisted Companies.
13 Appendix (Page No. – 149)
13.1 Discussion Guide
13.2 Knowledge Store: Marketsandmarkets’ Subscription Portal
13.3 Available Customizations
13.4 Related Reports
13.5 Author Details